Brighthouse Finl (NASDAQ:BHF) Stock

BRIGHTHOUSE FINANCIAL INC

Brighthouse Finl

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.

Brighthouse Financial, Inc. - Common Stock

Brighthouse Financial Inc

Brighthouse Financial, Inc. - Junior Subordinated Debentures due 2058

Brighthouse Financial, Inc. - Depositary shares each representing a 1/1,000th Interest in a Share of 4.625% Non-Cumulative Preferred Stock, Series D

Brighthouse Financial, Inc. - depositary shares, each representing a 1/1,000th interest in a share of 5.375% Non-Cumulative Preferred Stock, Series C

Brighthouse Financial, Inc. - Depositary Shares, each representing a 1/1,000th interest in a share of 6.750% Non-Cumulative Preferred Stock, Series B

Brighthouse Financial, Inc. - Depositary Shares 6.6% Non-Cumulative Preferred Stock, Series A

Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.16) by 75 percent. This is a 89.47 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $11.79 million which missed the analyst consensus estimate of $15.42 million by 23.55 percent. This is a 34.63 percent decrease over sales of $18.03 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

FLGC

Flora Growth Q1 EPS $(0.04) Beats $(0.16) Estimate, Sales $11.79M Miss $15.42M Estimate

Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year.

ANEB

Anebulo Pharmaceuticals Q3 EPS $(0.04) Beats $(0.05) Estimate

Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) reported quarterly losses of $(0.04) per share. This is a 20 percent increase over losses of $(0.05) per share from the same period last year. The company reported $22.92 thousand in sales this quarter. This is a 24.66 percent decrease over sales of $30.42 thousand the same period last year.

LWLG

Lightwave Logic Q1 EPS $(0.04) Up From $(0.05) YoY, Net Sales $22.92K Down From $30.42K YoY

Ambase (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABCP#OTC">ABCP</a>) reported quarterly losses of $(0.02) per share. This is a 60 percent increase over losses of $(0.05) per share from the same period last year.

ABCP

Ambase Q1 EPS $(0.02) Up From $(0.05) YoY

Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) reported quarterly losses of $(0.34) per share. This is a 100 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $3.39 million in sales this quarter. This is a 1.77 percent increase over sales of $3.33 million the same period last year.

SATL

CORRECTION: Satellogic Q1 EPS $(0.34) Down From $(0.17) YoY, Sales $3.39M Up From $3.33M YoY

McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) has outperformed the market over the past 20 years by 3.89% on an annualized basis producing an average annual return of 12.19%. Currently, McDonald's has a market capitalization of $220.59 billion. 
Buying $1000 In MCD: If an investor had bought $1000 of MCD stock 20 years ago, it would be worth $9,967.39 today based on a price of $308.75 for MCD at the time of writing.
<h3>McDonald's's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747174516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In McDonald's 20 Years Ago Would Be Worth Today

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $20 price target.

Price Target

Analyst Ratings

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Chardan Capital analyst Keay Nakae maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy and maintains $25 price target.

KRRO

Chardan Capital Maintains Buy on Korro Bio, Maintains $25 Price Target

General

EXEL

Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors

Reality competition "Beast Games"<a href="https://www.benzinga.com/general/entertainment/24/03/37809533/mrbeast-confirms-beast-games-on-amazon-prime-video-with-1-000-contestants-5m-prize-its-gonn"> from the mind of</a> content creator MrBeast is returning for two more seasons on Prime Video, the streaming platform from Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
MrBeast says he hopes this time the show doesn't lose him as much money, but he promises to make it bigger than the first season.
What Happened: A first season of "Beast Games" set several records, including 44 Guinness World Records, and had a massive $10 million payout to the winner from 1,000 contestants, but also created a <a href="https://www.benzinga.com/general/entertainment/25/02/43903423/mrbeast-calls-his-amazon-deal-for-beast-games-a-financial-mistake-this-is-the-price-you-have-to-pay">financial loss for MrBeast.</a>
The content creator, also known as Jimmy Donaldson, announced on social media that "Beast Games" has been renewed for two more seasons with Prime Video.
"Y'all are not ready for the big stuff we have planned," MrBeast <a href="https://x.com/MrBeast/status/1922068781058109819">said </a>in the post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Prime video has renewed Beast Games for not one but TWO MORE SEASONS!! Y'ALL ARE NOT READY FOR THE BIG STUFF WE HAVE PLANNED &#x1f970;&#x1f970;&#x1f970; <a href="https://t.co/oc5hWKBEnq">pic.twitter.com/oc5hWKBEnq</a>
&mdash; MrBeast (@MrBeast) <a href="https://twitter.com/MrBeast/status/1922068781058109819?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
A user asked MrBeast how he can make the show "go bigger" without the fear of going bankrupt, while asking about his loss on the first season.
"Going bigger is my specialty, that's the least of my concerns haha. Yeah, ideally don't lose 8 figures though," MrBeast replied.
The first season was the most-watched unscripted series on Prime Video, according to a <a href="https://variety.com/2025/tv/news/mrbeast-beast-games-renewed-two-seasons-prime-video-1236392387/">report </a>from Variety. The series had 50 million viewers in the first 25 days after its Dec. 19 premiere.
MrBeast has 32.5 million followers on X and 394 million subscribers on YouTube, ranking as the top followed account on the video platform.
The popularity of the content creator helped boost viewership for Prime Video and could do the same for two more seasons.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/05/38860861/amazon-betting-on-game-shows-for-streaming-growth-mrbeast-travis-kelce-pop-culture-jeopardy">Amazon Betting On Game Shows For Streaming Growth: MrBeast, Travis Kelce, Pop Culture Jeopardy And More</a>
What's Next: Based on the "Beast Games" <a href="https://www.beastgames.com/">website</a>, it looks like season 2 is still casting. The website says casting is open to people aged 18 or older who can legally travel and re-enter the U.S. for up to six consecutive weeks during the period of May to July 2025.
Contestants must also be free of any obligations including personal, family or work during the designated time period of filming for the show. Another interesting casting nugget is that any current candidates for public office or people intending to run for public office within one year as of July 1, 2026, can not participate in the show.
To get cast on the second season of "Beast Games," contestants need to submit their information along with a one-minute video about themselves that includes answers to some of the following questions:
<ul class="wp-block-list">
<li>"What was your favorite challenge from BEAST GAMES Season 1, and why?</li>
<li>"Who was your favorite contestant from Season 1, and what made them stand out to you?</li>
<li>"What makes you an unforgettable competitor?"</li>
<li>"What would you do with $5,000,000?"</li>
</ul>
Contestants on "Beast Games" are tested with challenges that are physical, mental and social and are also offered bribes to leave the game along the way.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44543735/mrbeast-is-writing-a-squid-game-style-thriller-and-media-companies-are-ready-to-bid-eight-figures-for-the-rights">MrBeast Is Writing A &#8216;Squid Game&#8217; Style Thriller And Media Companies Are Ready To Bid Eight-Figures For The Rights</a></li>
</ul>
Photo: Joe Seer via Shutterstock

Entertainment

Media

AMZN

MrBeast Teases Two More Seasons Of 'Beast Games' After Losing Millions: 'Ideally Don't Lose 8 Figures'

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $14 price target.

COYA

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Mannatech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEX#NASDAQ">MTEX</a>) reported quarterly losses of $(0.80) per share. This is a 226.98 percent decrease over earnings of $0.63 per share from the same period last year. The company reported $26.56 million in sales this quarter. This is a 9.63 percent decrease over sales of $29.39 million the same period last year.

MTEX

Mannatech Q1 EPS $(0.80) Down From $0.63 YoY, Sales $26.56M Down From $29.39M YoY

Wells Fargo analyst Yanan Zhu downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Overweight to Equal-Weight and lowers the price target from $11 to $0.1.

Downgrades

AFMD

Wells Fargo Downgrades Affimed to Equal-Weight, Lowers Price Target to $0.1

Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) reported quarterly losses of $(0.09) per share. This is a 91.89 percent increase over losses of $(1.11) per share from the same period last year. The company reported $343.00 thousand in sales this quarter. This is a 435.94 percent increase over sales of $64.00 thousand the same period last year.

WATT

UPDATE: Energous Q1 Adj. EPS $(0.09) Up From $(1.11) YoY, Sales $343.00K Up From $64.00K YoY

Fifth District Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDSB#NASDAQ">FDSB</a>) reported quarterly earnings of $0.02 per share. The company reported $3.20 million in sales this quarter.

FDSB

Fifth District Bancorp Q1 EPS $0.02, Sales $3.20M

Electra Battery Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>) reported quarterly losses of $(0.61) per share. This is a 4.69 percent increase over losses of $(0.64) per share from the same period last year.

ELBM

Electra Battery Materials Q1 EPS $(0.61) Up From $(0.64) YoY

MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) reported quarterly losses of $(0.39) per share. This is a 71.53 percent increase over losses of $(1.37) per share from the same period last year.

MEIP

MEI Pharma Q3 GAAP EPS $(0.39) Up From $(1.37) YoY

Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) reported $12.81 million in sales this quarter. This is a 10.66 percent increase over sales of $11.57 million the same period last year.

BIYA

Baiya International Group FY24 EPS $0.00 Up From $(0.10) YoY, Sales $12.81M Up From $11.57M YoY

Scotiabank analyst Orest Wowkodaw maintains Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) with a Sector Outperform and raises the price target from C$12 to C$12.5.

TSX:HBM

Scotiabank Maintains Sector Outperform on Hudbay Minerals, Raises Price Target to C$12.5

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.15, with a high estimate of $8.00 and a low estimate of $5.00. Observing a downward trend, the current average is 13.38% lower than the prior average price target of $7.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1747173673_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive GoodRx Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.25</td>
<td>$6.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to GoodRx Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GoodRx Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of GoodRx Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of GoodRx Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GDRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GoodRx Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind GoodRx Holdings</h2>
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
<h3>Unraveling the Financial Story of GoodRx Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining GoodRx Holdings's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.57% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: GoodRx Holdings's net margin excels beyond industry benchmarks, reaching 5.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): GoodRx Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 1.6%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): GoodRx Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.82% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: GoodRx Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.83, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Brighthouse Finl

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL